15-Year watch: tracking blood cancer patients after revolutionary cell therapy
NCT ID NCT06652633
Summary
This study follows 546 patients who received Galapagos CAR T-cell therapies for blood cancers to monitor their health for 15 years after treatment. Researchers will track long-term safety, check if the treatment cells remain in the body, and watch for any delayed side effects. The goal is to understand the lasting benefits and risks of these advanced cancer therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Academisch Medisch Centrum
RECRUITINGAmsterdam, 1105 AZ, Netherlands
-
Amsterdam UMC
RECRUITINGAmsterdam, 1081 HV, Netherlands
-
Antwerp University Hospital
RECRUITINGEdegem, 2650, Belgium
-
Centre Hospitalier Universitaire (CHU) De Liège
RECRUITINGLiège, 4032, Belgium
-
Hospital Clinic De Barcelona
RECRUITINGBarcelona, 08036, Spain
-
Leids University Medical Center (LUMC)
RECRUITINGLeiden, 2333 ZA, Netherlands
Conditions
Explore the condition pages connected to this study.